We help founders transform industries.

Venture investment in technology and healthcare

GLOBAL MULTI-STAGE INVESTOR, WORLD-CLASS NETWORK

Approach

Sixty Degree Capital invests in companies creating meaningful change in their industries, across sectors (software, digital infrastructure, healthcare, biotech) and across stages (as early as Series A, as late as pre-IPO).

Advantage

We have a world-class network, specialized in-house expertise, and relationships with marquee investors. This differentiation enables us to support our portfolio companies and generate exceptional returns for our investors.

Our Portfolio

Antios-Exit-sm
Aqua-Security
Arcellx
ArcticWolf
Bionaut
Cato
Cincor
Clearcover
d0d9fdd7-953f-43a2-94d3-f0bcb1ffd923
Datagrail-bot
Docker
Engage
Everlyhealth
Everside
Fog
5e903eb7-2892-4cbe-b17b-da455d1c6c8a
Grubmarket
Inspirna
Korro-IPO-sm
LibraThera
Lime
Macrometa
Miovision
MonteRosa
Navan
Nested
Nextpoint
NorthernBio
Paperspace
Pipeline-bot
Pragma-bot
RadiusAgent
Reflexion
Schrodinger
StiveHealth-mid
TactAI
Tknife
TransThera
Veem
4c6090dd-70f7-4991-8bd0-7955c8e037a9
Aqua-Security
ArcticWolf
Cato
Clearcover
d0d9fdd7-953f-43a2-94d3-f0bcb1ffd923
Datagrail-bot
Docker
Everlyhealth
5e903eb7-2892-4cbe-b17b-da455d1c6c8a
Grubmarket
Lime
Macrometa
Miovision
Navan
Paperspace
Pragma-bot
RadiusAgent
Schrodinger
TactAI
Veem
4c6090dd-70f7-4991-8bd0-7955c8e037a9
Antios-Exit-sm
Arcellx
Bionaut
Cincor
Engage
Everside
Fog
Inspirna
Korro-IPO-sm
LibraThera
MonteRosa
Nextpoint
Nested
NorthernBio
Pipeline-bot
Reflexion
Schrodinger
StiveHealth-mid
Tknife
Turnstone
TransThera

Blog/News

News

Sixty Degree Capital Celebrates Final Close of Fund III, Raising $250M for VC Investment in High-Growth Tech Companies

November 23, 2023 – Sixty Degree Capital is excited to announce the final close of its third venture capital fund, with $250M earmarked for high-growth companies from Series A to pre-IPO stages across enterprise software and healthcare.Fund III is already actively deploying capital to industry-leading ventures including Cato Networks, Docker, NextPoint, Strive Health, Navan, Aqua…
Read More

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

– Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021 August 02, 2021 08:00 ET| Source: T-knife Therapeutics SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for…
Read More

Everside Health Announces $164 Million in Growth Equity Funding from NEA and New Investors

Existing investors NEA, Oak HC/FT and Alta Partners, and new investors, including Endeavor Catalyst, joined the round Funding will accelerate growth, enhance Everside’s technology stack to facilitate predictive, whole-patient care, and support potential M&A opportunities DENVER, July 25, 2022 /PRNewswire/ — Everside Health, LLC, a leading national direct primary care provider, today announced that it has raised $164 million in growth equity funding. Longstanding investor…
Read More

KITE AND ARCELLX ANNOUNCE STRATEGIC COLLABORATION TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA

— Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing — SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for…
Read More

CinCor Pharma to be Acquired by AstraZeneca

January 09, 2023 02:05 ET| Source: CinCor Pharma IncFollow WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We are excited about the…
Read More

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

HAYWARD, Calif.–(BUSINESS WIRE)–RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers. The company will host a live-stream event featuring both its co-founder and CEO discussing the breakthrough significance of SCINTIX…
Read More